Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label extension of AKCEA-APOCIII-LRX in familial chylomicronemia syndrome
NL-OMON51487Phase 3Recruiting
- Sponsor
- Ionis Pharmaceuticals
- Start
- Oct 2022
- Modality
- Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Single-strand DNA → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Modified DNA Oligonucleotides → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of olezarsen in primary chylomicronemia (FCS), sponsored by Ionis Pharmaceuticals. Primary endpoints: Platelet count decrease of at least 30%, Platelet count decrease of at least 50% and 11 more. Started Oct 2022; status: recruiting.
02
Drugs
olezarsen
03
Conditions
primary chylomicronemia (FCS)
Beyond the preview
Go deeper on NL-OMON51487.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON51487.